Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof

US11730775B2 · kind B2 · utility

Assignee

• Seres Therapeutics, Inc. · US

Inventors

• Gregory McKenzie · Arlington, US
• Mary-Jane Lombardo McKenzie · Arlington, US
• David N. Cook · Lafayette, US
• Marin Vulic · Boston, US
• Geoffrey von Maltzahn · Boston, US
• Brian Goodman · Brookline, US
• John Grant Aunins · Cambridge, US
• Matthew R. Henn · Somerville, US
• David Arthur Berry · Brookline, US
• Jonathan Winkler · Boston, US

Key dates

• Filing date: Apr 5, 2021
• Grant date: Aug 22, 2023
• Expiry date: Jul 17, 2041

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed herein are therapeutic compositions containing non-pathogenic, germination-competent bacterial spores, for the prevention, control, and treatment of gastrointestinal diseases, disorders and conditions and for general nutritional health.